The lung ciliary assay is for use in preclinical drug development
A leading drug discovery partner and specialist in the development of in-vitro models and bespoke assay services, Newcells Biotech, has launched Cillabeat, a proprietary software and application Lung Ciliary Beat Frequency Analysis assay.
The edge software will enable researchers to assess the effect of drugs and chemicals on the function of the ciliated cells within the lung's small airways.
The technology has been extensively tested using Newcells’ physiologically-relevant small airway epithelial cell (SAEC) model, demonstrating high sensitivity and predictiveness for safety and efficacy in pre-clinical drug development.
Launching alongside CiliaBeat and designed to harness the full capabilities of the software, Newcells’ Lung Ciliary Beat Frequency Analysis assay expands the company’s services portfolio. The new assay generates reliable and predictive in-vitro data on the activity of the beating cilia within the airways.
It allows the assessment of dosing on mucus clearance, cilia function and evaluation of drug efficacy in reversing disease-like conditions. These parameters are particularly important to inform discovery and development for new drugs targeting lung conditions such as Chronic Obstructive Pulmonary Disorder (COPD), bronchiectasis, as well as the impact of airborne chemicals.
Developed to address a market gap for a software with high sensitivity, stability and speed, CiliaBeat complements the company’s recently launched high-content and high-throughput imaging suite1, which the company argues further stregthens its position as a provider of market-leading imaging capabilities. It also helps meet meet growing customer demand for more data-rich and predictive preclinical studies.
The software is capable of rapid and unbiased analysis, maximising video inputs of beating ciliated cells while also minimising background noise.
The high-definition videos are captured using an optimised set-up for increased sensitivity, generating accurate and in-depth datasets to accelerate programmes and inform lead compound selection, including for fast-acting drugs.
CEO and co-founder, Newcells Biotech, Dr Mike Nicholds, said: “Our team is highly experienced in development of robust and predictive assays for drugs targeting the lung. CiliaBeat complements our existing capabilities, giving customers more options to gain physiologically-relevant insights into this crucial organ type.”
He added: “We prioritise innovation, driving forward the scale and depth of offerings to customers, to support decision-making and accelerate their drug development processes.”
